Larimar Therapeutics, Inc. Net Income Loss

• Larimar Therapeutics, Inc. showed a decrease of -105.5% in Net Income Loss from 2024 to 2025.
• This data is from Larimar Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
• XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 14 years of available data (2012 to 2025), Larimar Therapeutics, Inc.'s Net Income Loss has declined by 1,093.6%.
• Historical annual values: Fiscal year 2025: -$165.67 million | Fiscal year 2024: -$80.60 million | Fiscal year 2023: -$36.95 million | Fiscal year 2022: -$35.36 million | Fiscal year 2021: -$50.64 million | Fiscal year 2020: -$42.48 million | Fiscal year 2019: -$23.13 million | Fiscal year 2018: -$61.37 million | Fiscal year 2017: -$52.03 million | Fiscal year 2016: -$57.88 million | Fiscal year 2015: -$74.29 million | Fiscal year 2014: -$36.48 million | Fiscal year 2013: -$14.03 million | Fiscal year 2012: -$13.88 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026